{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:07:14Z","timestamp":1747188434720,"version":"3.40.5"},"reference-count":22,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Red cell antigen genotyping is commonly performed on patients requiring chronic transfusion support, such as sickle cell disease and thalassaemia. The Immucor HEA BeadChip\u2122 test, in addition to assessing red cell antigen expression, can also detect the haemoglobin S (HbS) mutation. Our aim was to compare HbS results using HEA BeadChip\u2122 performed at the Australian Red Cross Lifeblood with conventional haemoglobin studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Patients with thalassaemia and sickle cell trait (SCT) or disease (SCD) referred for red cell genotyping between 2017 and 2019 were assessed. The HbS result obtained from HEA BeadChip\u2122 was compared with that obtained from high\u2010performance liquid chromatography (HPLC) performed by the referring pathology provider.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One\u2010hundred and nineteen cases had comparable HPLC and HEA BeadChip\u2122 results. On HEA BeadChip\u2122 testing, 40 cases showed a negative HbS result, 31 cases showed HbS+ and 47 cases showed HbS++. There was one case with \u2018low signal\u2019 result. Of the negative HbS cases, there was none with SCT. The HbS+ group comprised a mixture of SCT and SCD due to compound heterozygosity for HbS and \u03b2\u2010thalassaemia mutations. The HbS++ group comprised predominantly SCD due to homozygosity for HbS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HEA BeadChip\u2122 is an accurate screening test for the detection of HbS. There were no false positives or false negatives. The identification of donors with the HbS mutation through the targeted genotyping programme would enable early intervention, improved donor management and reduced wastage.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.13289","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T17:14:31Z","timestamp":1651857271000},"page":"1001-1005","source":"Crossref","is-referenced-by-count":2,"title":["Haemoglobin S testing using <scp>HEA BeadChip<\/scp>\u2122 technology: Lifeblood comparison with clinical diagnosis"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-6219","authenticated-orcid":false,"given":"Philip","family":"Wong","sequence":"first","affiliation":[{"name":"Clinical Services and Research Australian Red Cross Lifeblood  Kelvin Grove Australia"},{"name":"School of Medicine University of Queensland  St Lucia Australia"},{"name":"Department of Cancer Care Services Toowoomba Hospital  Toowoomba Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoma","family":"Baidya","sequence":"additional","affiliation":[{"name":"Clinical Services and Research Australian Red Cross Lifeblood  Kelvin Grove Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Daly","sequence":"additional","affiliation":[{"name":"Clinical Services and Research Australian Red Cross Lifeblood  Kelvin Grove Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Powley","sequence":"additional","affiliation":[{"name":"Clinical Services and Research Australian Red Cross Lifeblood  Kelvin Grove Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470988787"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14346"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/voxs.12416"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14383"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12061"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13084"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14611"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001143"},{"key":"e_1_2_8_10_1","unstructured":"Red cell molecular genotyping information sheet. Australian Red Cross Lifeblood; 2019 [updated 2019 Nov 18; cited 2020 Apr 11]. Available from:https:\/\/transfusion.com.au\/node\/2232"},{"volume-title":"BeadChip molecular immunohematology: toward routine donor and patient antigen profiling by DNA analysis","year":"2011","author":"Moulds JMNP","key":"e_1_2_8_11_1"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00206.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2019-075"},{"key":"e_1_2_8_14_1","unstructured":"Australian Red Cross Lifeblood.Guidelines for the selection of blood donors. Australia.2019."},{"key":"e_1_2_8_15_1","unstructured":"Guide for the preparation use and quality assurance of blood components: recommendation No. R (95) 15. European Directorate for the Quality of Medicines & HealthCare. Strasbourg: Council of Europe;2017."},{"key":"e_1_2_8_16_1","unstructured":"BarnesS.Sickle cell trait and apheresis. Joint United Kingdom Blood Transfusion Services and Health Protection Agency Professional Advisory Committee.2012:7."},{"key":"e_1_2_8_17_1","first-page":"105 [Abstract P","article-title":"Screening for sickle cell trait in blood donors by HEA BeadChip test","volume":"103","author":"Yang JC","year":"2012","journal-title":"Vox Sang"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.25.5.458"},{"key":"e_1_2_8_19_1","unstructured":"FAQ: leucodepletion of red cells and platelets: Australian Red Cross Lifeblood; 2019 [updated 2019 Nov 15; cited 2020 Mar 21]. Available from:https:\/\/transfusion.com.au\/blood_products\/components\/leucodepletion"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2004.03.002"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0041-1132.2004.04086.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2021.103146"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16403"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13289","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.13289","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:55:37Z","timestamp":1692842137000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/vox.13289"],"URL":"https:\/\/doi.org\/10.1111\/vox.13289","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"type":"print","value":"0042-9007"},{"type":"electronic","value":"1423-0410"}],"subject":[],"published":{"date-parts":[[2022,5,6]]}}}